

Andrey U Kulikov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5757827/publications.pdf>

Version: 2024-02-01

237
papers

150
citations

1478505

6
h-index

1474206

9
g-index

241
all docs

241
docs citations

241
times ranked

132
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of reversed phase high performance liquid chromatography method for determination of dexpanthenol in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 983-988.	2.8	13
2	Mathematical Modeling for Financial Analysis of an Enterprise: Motivating of Not Open Innovation. Journal of Open Innovation: Technology, Market, and Complexity, 2021, 7, 79.	5.2	12
3	Optimization of the Structure of the Investment Portfolio of High-Tech Companies Based on the Minimax Criterion. Energies, 2021, 14, 4647.	3.1	12
4	Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making. Value in Health Regional Issues, 2017, 13, 61-66.	1.2	11
5	Improving the Development Technology of an Oil and Gas Company Using the Minimax Optimality Criterion. Energies, 2021, 14, 3177.	3.1	9
6	Cost-Effectiveness Analysis of Cerebrolysin In The Treatment of Patients With Acute Ischemic Stroke Moderate and Severe Degrees of Severity In The Russian Federation. Value in Health, 2015, 18, A705.	0.3	5
7	Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme. Value in Health, 2014, 17, A381.	0.3	3
8	Cost-Effectiveness Analysis Of Obinutuzumab/Chlorambucil Vs Rituximab/Chlorambucil In Treatment Of Chronic Lymphocytic Leukemia. Value in Health, 2015, 18, A460.	0.3	3
9	Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma. Pulmonologiya, 2018, 28, 50-60.	0.8	3
10	Pharmacoeconomic analysis of cellex application in the treatment of cerebrovascular accident. Pharmacoeconomics Theory and Practice, 2016, 4, 61-63.	0.1	3
11	PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia. Value in Health, 2011, 14, A450.	0.3	2
12	PMS25 Evaluation of Direct Costs for the Treatment of Active Juvenile Rheumatoid Arthritis Using Biologics. Value in Health, 2011, 14, A306.	0.3	2
13	Budget Impact Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A130.	0.3	2
14	PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION. Value in Health, 2018, 21, S412.	0.3	2
15	Pharmacoeconomic analysis of the use of the kuvan drug product in phenylketonuric patients. Pharmacoeconomics Theory and Practice, 2015, 3, 20-21.	0.1	2
16	Pharmacoeconomic analysis to compare subcutaneous versus intravenous mabthera® (rituximab) in patients with follicular lymphoma. Pharmacoeconomics Theory and Practice, 2015, 3, 17-19.	0.1	2
17	Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconomics Theory and Practice, 2015, 3, 71-78.	0.1	2
18	Pharmacoeconomic evaluation of Secukinumab use as a first-line biologic in patients with psoriatic arthritis. Pharmacoeconomics Theory and Practice, 2018, 6, 20-28.	0.1	2

#	ARTICLE	IF	CITATIONS
19	Pharmacoeconomics for the Health Care Managers: decision-making algorithm based on pharmacoeconomic assessments. <i>Pharmacoeconomics Theory and Practice</i> , 2014, 2, 13-20.	0.1	2
20	Analysis of pharmacoeconomic and clinical economic studies published in the scientific electronic library "LIBRARY.RU" (RSCI) for the period from 2005 to 2015. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 60-108.	0.1	2
21	Comparative analysis of the methodology of pharmacoeconomic assessment according to the origin (dated 08.28.2014) and the current (dated 10.29.2018) version of the government degree of the Russian Federation №871. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 7-16.	0.1	2
22	Pharmacoeconomic evaluation of drugs used in enzyme replacement therapy mucopolysaccharidosis type II. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 10-15.	0.1	2
23	Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. <i>Russian Journal of Cardiology</i> , 2019, , 76-86.	1.4	2
24	PIN4 ANTIBIOTIC THERAPY OF NOSOCOMIAL INFECTION IN THE INTENSIVE CARE UNIT: A COST-EFFECTIVENESS ANALYSIS. <i>Value in Health</i> , 2006, 9, A299.	0.3	1
25	PRS8 OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA. <i>Value in Health</i> , 2009, 12, A300.	0.3	1
26	PCN55 COST OF TREATMENT OF BREAST CANCER IN RUSSIA. <i>Value in Health</i> , 2010, 13, A261.	0.3	1
27	PND21 Multiple Sclerosis in Russian Federation: Evaluation of Social and Economical Burden in Real Clinical Practice. <i>Value in Health</i> , 2012, 15, A549.	0.3	1
28	Pharmacoeconomic Analysis of Anti-Inhibitor Coagulant Complex (AICC) in the Treatment of Inhibitor Hemophilia. <i>Value in Health</i> , 2013, 16, A379.	0.3	1
29	Pharmacoeconomic Analysis of Axitinib as Second-Line Treatment for Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2014, 17, A638-A639.	0.3	1
30	Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation. <i>Value in Health</i> , 2014, 17, A75.	0.3	1
31	Budget Impact Analysis of Canacinumab In The Treatment of Patients With Muckle-Wells Syndrome In The Russian Federation. <i>Value in Health</i> , 2015, 18, A663.	0.3	1
32	Budget Impact Analysis of Botulinum Toxin Type A Treatment for Cerebral Palsy In The Russian Federation. <i>Value in Health</i> , 2015, 18, A752.	0.3	1
33	Budget Impact Analysis of Dasatinib as a Second-Line Therapy in Patients with Chronic Myelogenous Leukemia (Cml) in the Russian Federation. <i>Value in Health</i> , 2015, 18, A441-A442.	0.3	1
34	Pharmacoeconomic Evaluation Of The Use Of Trastuzumab For Subcutaneous Administration Compared To Intravenous Dosage Form In The Treatment Of Breast Cancer. <i>Value in Health</i> , 2015, 18, A463.	0.3	1
35	Cost-Effectiveness Analysis of Botulinum Toxin Type a Treatment for Cerebral Palsy. <i>Value in Health</i> , 2015, 18, A734.	0.3	1
36	Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation. <i>Value in Health</i> , 2015, 18, A699.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomic Study Of The Use Of Rituximab For Subcutaneous Administration In The Treatment Of Follicular Lymphoma. Value in Health, 2015, 18, A463.	0.3	1
38	PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S554.	0.3	1
39	The economic burden of multiple sclerosis. Pharmacoeconomics Theory and Practice, 2013, 1, 3-34.	0.1	1
40	Pharmacoeconomic analysis of the use of granulocyte colonystimulating factor drugs in prophylaxis of febrile neutropenia in cancer patients under healthcare settings in the Russian Federation. Pharmacoeconomics Theory and Practice, 2016, 4, 195-201.	0.1	1
41	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Pharmacoeconomics Theory and Practice, 2015, 3, 86-90.	0.1	1
42	Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents. Diabetes Mellitus, 2010, 13, 101-110.	1.9	1
43	Pharmacoeconomic analysis of crizotinib use in first-line chemotherapy for alk-positive non-small cell lung cancer. Pharmacoeconomics Theory and Practice, 2014, 2, 25-28.	0.1	1
44	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Pharmacoeconomics Theory and Practice, 2015, 3, 86-90.	0.1	1
45	Pharmacoeconomic analysis of dasatinib as a second-line therapy in patients with chronic myelogenous leukemia. Pharmacoeconomics Theory and Practice, 2015, 3, 92-95.	0.1	1
46	Economic burden of multiple sclerosis in the Republic of Belarus. Pharmacoeconomics Theory and Practice, 2015, 3, 96-101.	0.1	1
47	Pharmacoeconomic analysis of beyodyme (pertuzumab+ trastuzumab [set]) in the treatment of patients with her2- positive metastatic breast cancer. Pharmacoeconomics Theory and Practice, 2015, 3, 36-39.	0.1	1
48	Pharmacoeconomic analysis of von willebrand factor/blood clotting factor viii concentrate (wilate) in the management of patients with von willebrand disease. Pharmacoeconomics Theory and Practice, 2015, 3, 74-81.	0.1	1
49	Assessing willingness-to-pay threshold for health technologies in the Russian Federation on the basis of purchasing power parity. Pharmacoeconomics Theory and Practice, 2015, 3, 10-14.	0.1	1
50	The cost-effectiveness of abatacept compared to adalimumab for adult patients with rheumatoid arthritis in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 31-36.	0.1	1
51	Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib. Pharmacoeconomics Theory and Practice, 2016, 4, 157-164.	0.1	1
52	Pharmacoeconomics analysis of the medicinal product Djopaxone-40 in treating multiple sclerosis. Pharmacoeconomics Theory and Practice, 2016, 4, 35-39.	0.1	1
53	Pharmacoeconomic Analysis of the Inclusion of Rivaroxaban in the Current Algorithms Prevention of the Strokein Patients With Atrial Fibrillation. Kardiologiya, 2016, 11_2016, 71-77.	0.7	1
54	Pharmacoeconomic analysis of the medicinal product javlor (vinflunine) in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Pharmacoeconomics Theory and Practice, 2015, 3, 86-90.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Pharmacoeconomic analysis of nivolumab in treatment of nonresectable stage III-IV melanoma among treatment-naive BRAF-mutated patients in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2017, 5, 47-47.	0.1	1
56	Pharmacoeconomic analysis of combination of daclatasvir and sofosbuvir in treatment of chronic hepatitis C (genotype 3) in the Russian Federation: among treatment-experienced patients. <i>Pharmacoeconomics Theory and Practice</i> , 2017, 5, 28-28.	0.1	1
57	Selection of a comparison technology for pharmacoeconomic analysis of innovative drugs. <i>Pharmacoeconomics Theory and Practice</i> , 2017, 5, 12-17.	0.1	1
58	Pharmacoeconomic analysis of a medicinal product neoton (phosphocreatine) in perioperative management of cardiac surgery patients with extracorporeal circulation, with ischemic heart disease or with chronic heart insufficiency. <i>Pharmacoeconomics Theory and Practice</i> , 2018, 5, 77-80.	0.1	1
59	Pharmacoeconomic analysis of infertility treatment in women with a suboptimal ovarian response. <i>Akusherstvo I Ginekologiya (Russian Federation)</i> , 2018, 6_2018, 77-84.	0.3	1
60	Learning Needs as a Reflection of Professional Interests among Health Experts. <i>Safety and Risk of Pharmacotherapy</i> , 2019, 7, 44-52.	0.2	1
61	Results of a Sociological Survey on the Needs of Drug Safety Monitoring Specialists for Information on the Creation of the Pharmacovigilance System Master File. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 84-89.	0.2	1
62	Pharmacoeconomic evaluation of various treatment options for respiratory distress syndrome in newborns. <i>Voprosy Ginekologii, Akusherstva I Perinatologii</i> , 2021, 20, 155-161.	0.3	1
63	Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. <i>Farmakoekonomika</i> , 2022, 15, 73-86.	1.2	1
64	Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 1-17.	0.5	1
65	PHP36 PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USING DRUGS FROM REIMBESMENT LIST IN RUSSIA. <i>Value in Health</i> , 2006, 9, A218.	0.3	0
66	PAA4 PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA PATIENTS. <i>Value in Health</i> , 2006, 9, A333.	0.3	0
67	PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT. <i>Value in Health</i> , 2007, 10, A45.	0.3	0
68	PND7 PHARMACOECONOMIC ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF THE IDIOPATHIC GENERALIZED EPILEPSIES. <i>Value in Health</i> , 2007, 10, A88.	0.3	0
69	PIN20 PHARMACOECONOMIC ANALYSIS OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA TREATMENT. <i>Value in Health</i> , 2007, 10, A165.	0.3	0
70	PUK5 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUNÂ® NEORALÂ®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION. <i>Value in Health</i> , 2007, 10, A314.	0.3	0
71	PUK6 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUNÂ® NEORALÂ®) IN COMPARISON WITH TACROLIMUS (PROGRAFÂ®) FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION. <i>Value in Health</i> , 2007, 10, A314-A315.	0.3	0
72	PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET. <i>Value in Health</i> , 2008, 11, A531-A532.	0.3	0

#	ARTICLE	IF	CITATIONS
73	PRS15 NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT. Value in Health, 2009, 12, A301.	0.3	0
74	PSY29 PHARMACOECONOMIC EVALUATION OF TREATMENT ANEMIA WITH ERYTHROPOIETIC AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS. Value in Health, 2009, 12, A380.	0.3	0
75	PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT. Value in Health, 2010, 13, A267.	0.3	0
76	PDB49 PHARMACOECONOMICS MODELING OF LONG TERM RESULTS OF TYPE 2 DIABETES MELLITUS TREATMENT IN PATIENTS USING MODERN INSULIN ANALOGUES IN CONTRAST TO ORAL ANTIDIABETIC DRUGS OR DIET. Value in Health, 2010, 13, A292.	0.3	0
77	PRS31 SHOULD SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) BE ADDED TO ROUTINE COPD TREATMENT WITH FENOTEROL/ IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC ASSESSMENT OF COPD TREATMENT BASED ON OBSERVATIONAL RESEARCH (PHACTOR). Value in Health, 2010, 13, A324.	0.3	0
78	PRS32 REGIONAL DIFFERENCES AS A BASIS FOR SENSITIVITY ANALYSIS OF COST-EFFECTIVENESS OF SALMETEROL + FLUTICASONE PROPIONATE (SAL/FP) VS. INHALED CORTICOSTEROIDS (MONO-ICS). Value in Health, 2010, 13, A324.	0.3	0
79	PND23 COST-EFFECTIVENESS EVALUATION OF LEVODOPA/CARBIDOPA/ ENTACAPONE IN TREATMENT OF PARKINSON DISEASE. Value in Health, 2010, 13, A392.	0.3	0
80	PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia. Value in Health, 2011, 14, A450-A451.	0.3	0
81	PCN46 Cost of Metastatic Prostate Cancer Treatment in the 12 Months Following Diagnosis per Patient in Russian Federation. Value in Health, 2011, 14, A442.	0.3	0
82	PRS47 Optima Model-Based Cost-Utility Analysis of Fixed Combination Salmeterol/Fluticasone Versus Non-Fixed Combination Budesonide/Formoterol in One Pack for Bronchial Asthma Treatment. Value in Health, 2011, 14, A496.	0.3	0
83	PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER. Value in Health, 2011, 14, A165.	0.3	0
84	PGI20 Pharmacoeconomic Study of Glutamine Dipeptide Usage During Total Parenteral Nutrition (TPN). Value in Health, 2011, 14, A395.	0.3	0
85	PRS37 The Impact of Regional Data on Cost-Effectiveness Results of Salmeterol/Fluticasone Propionate (SAL/FP) + Fenoterol/Ipratropium Bromide (Fen/IB) Versus Fen/IB Only in COPD Treatment. Value in Health, 2011, 14, A494.	0.3	0
86	PCN82 Pharmacoeconomical Evaluation of Multiple Mieloma Treatment With Lenalidomide in the Russian Federation. Value in Health, 2012, 15, A222.	0.3	0
87	PCN80 Economic Evaluation of Sunitinib for the First-Line Treatment of Metastatic Renal Cell Carcinoma in Russian Federation. Value in Health, 2012, 15, A222.	0.3	0
88	PIH8 Comparative Pharmacoeconomic Study of Disposable and Reusable Gowns and Drapes. Value in Health, 2012, 15, A537.	0.3	0
89	PRS12 Budget Impact Analysis of Tiotropium Bromide Versus Ipratropium Bromide on the Top of Standard Therapy in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Russian Federation. Value in Health, 2012, 15, A53.	0.3	0
90	PCV52 Urapidil in Treatment of Hypertension Urgencies in the Russian Federation: Cost-Effectiveness Analysis. Value in Health, 2012, 15, A121.	0.3	0

#	ARTICLE	IF	CITATIONS
91	PIN54 Evaluation of Skin Tests in the Diagnostics of Tuberculosis Infection. Value in Health, 2012, 15, A395.	0.3	0
92	PCN79 Pharmacoeconomic Evaluation of Acute Myeloid Leukemia and MDS Syndromes (Intermediate) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.3	0
93	PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation. Value in Health, 2012, 15, A426.	0.3	0
94	PCV21 Budget Impact Analysis of Introducing of pCMV-VEGF165 for Treatment of Critical Limb Ischemia From the Russian Health Care System Perspective. Value in Health, 2012, 15, A365.	0.3	0
95	PND43 Cost-Utility Analysis Patients With Low Back Pain After Treatment Intraosseous Blockades. Value in Health, 2012, 15, A553.	0.3	0
96	PSS6 Pharmacoeconomic Evaluation of Open-Angle Glaucoma Treatment in Russia. Value in Health, 2012, 15, A250.	0.3	0
97	Budget impact analysis of quetiapine versus aripiprazole or olanzapine on the top of standard therapy in the treatment of bipolar disorder in Russian Federation. Value in Health, 2013, 16, A58.	0.3	0
98	Comparative Pharmacoeconomic Analysis Of Budesonide/Formoterol Maintenance And Reliever Therapy In The Treatment Of Bronchial Asthma In Russian Federation. Value in Health, 2013, 16, A235-A236.	0.3	0
99	Pharmacoeconomic Study of Nutrition Support (NS) Usage During Intensive Treatment. Value in Health, 2013, 16, A379.	0.3	0
100	The Review of Publications of Pharmacoeconomic Research in Russia During 2007-2012. Value in Health, 2013, 16, A580.	0.3	0
101	Budget Impact Analysis (Bia) Of Cabazitaxel Introduction In Treatment Of Metastatic Hormone-Refractory Prostate Cancer (Mhrpc) In Russian Federation. Value in Health, 2013, 16, A132.	0.3	0
102	Pharmacoeconomic Assessment of Ranibizumab in the Treatment of the Diabetic Retinopathy in the Russian Federation. Value in Health, 2013, 16, A503.	0.3	0
103	Cost-Effectiveness of Antimicrobials as Treatment for Patients with Complicated Skin and Soft Tissues Infections: A Comparison Between Ceftaroline, Linezolid and Vancomycin in the Russian Health Care. Value in Health, 2013, 16, A355.	0.3	0
104	Peritonitis Fluid Treatment in Russian Federation: Evaluation of Economical Burden in Real Clinical Practice. Value in Health, 2013, 16, A494.	0.3	0
105	Budget Impact Analysis of Switching from DPT and Monovalent Vaccines to DTaPâ€“IPV-Hib Combined Vaccine into Russian Immunization Schedule. Value in Health, 2013, 16, A343.	0.3	0
106	Cost-effectiveness of atypical antipsychotics as treatment for patients with bipolar disorder (episodes) Tj ETQq0 0 0 rgBT /Overlock 10 T the Russian health care. Value in Health, 2013, 16, A61-A62.	0.3	0
107	Cost-effectiveness of atypical antipsychotics for the treatment of relapse prevention for bipolar disorder: The russian perspective. Value in Health, 2013, 16, A62.	0.3	0
108	Economic Evaluation of Liraglutide for Treatment of Type 2 Diabetes Mellitus in the Russian Federation. Value in Health, 2013, 16, A443.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Budget Impact Analysis of Ceftaroline Versus Linezolid or Vancomycin on the Top of Standard Therapy in the Treatment of Complicated Skin and Soft Tissues Infections in Russian Federation. Value in Health, 2013, 16, A345.	0.3	0
110	Pharmacoeconomic Analysis Of Docetaxel In The Adjuvant Therapy Of Breast Cancer. Value in Health, 2013, 16, A132.	0.3	0
111	The cost-effectiveness of quetiapine, aripiprazole or olanzapine in patients with bipolar depression in the Russian Federation. Value in Health, 2013, 16, A62.	0.3	0
112	Long-Term Modeling of Using Manually Coded and Autocoded Blood Glucose Meters in Diabetes Treatment. Value in Health, 2014, 17, A333.	0.3	0
113	Budget Impact Evaluation Of Treatment With A Low Protein Diet And Ketoanalogues Of Essential Aminoacids For Predialysis Patients In Russian Federation. Value in Health, 2014, 17, A467.	0.3	0
114	Cost Analysis In the Treatment of Patients With Systemic Lupus Erythematosus In Russian Federation. Value in Health, 2014, 17, A527.	0.3	0
115	Pharmacoeconomic Study of Botulinium Toxin Type a in Treatment of Post-Stroke Spasticity in the Russian Federation: Cost-Effectiveness Analysis. Value in Health, 2014, 17, A395.	0.3	0
116	Cost-Effectiveness Analysis of Autocoded and Manually Coded Blood Glucose Meters In Diabetes Treatment. Value in Health, 2014, 17, A337-A338.	0.3	0
117	Budget Impact Analysis of Bevacizumab and Anti-Egfr with Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation. Value in Health, 2014, 17, A75.	0.3	0
118	Cost Of Illness Analysis Of Dialysis In Different Regions Of Russia. Value in Health, 2014, 17, A292-A293.	0.3	0
119	Pharmacoeconomic Assessment Of Treatment With A Low Protein Diet And Ketoanalogues Of Essential Aminoacids For Predialysis Patients In Russian Federation. Value in Health, 2014, 17, A291.	0.3	0
120	Cost Of Illness Analysis Of Chronic Kidney Disease In The Entire Population Of The Russian Federation. Value in Health, 2015, 18, A187.	0.3	0
121	Cost Effectiveness Analysis Of Budesonid Easyhaler In The Treatment Of Asthma In Children In The Russian Federation. Value in Health, 2015, 18, A501.	0.3	0
122	Pharmacoeconomic Analysis of Urothelial Transitional Cell Cancer Treatment with Vinflunine in Patients Resistant to the Platinum-Based Treatment Regimes. Value in Health, 2015, 18, A443-A444.	0.3	0
123	Budget Impact Analysis of Blood Clotting Factor Concentrates In The Treatment of Von Willebrand Disease. Value in Health, 2015, 18, A663.	0.3	0
124	Budget Impact Analysis of Botulinium Toxin Type A In Treatment of Post-Stroke Spasticity In The Russian Federation. Value in Health, 2015, 18, A157.	0.3	0
125	Cost-Effectiveness Analysis of Canacinumab In The Treatment of Patients Suffering From Systemic Juvenile Idiopathic Arthritis In Russian Federation. Value in Health, 2015, 18, A646.	0.3	0
126	Modeling of Societal Costs Under Different Treatment Schemes of Post-Stroke Spasticity In The Russian Federation. Value in Health, 2015, 18, A157-A158.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Pharmacoepidemiologic Modeling of Treatment Hiv-Infected Patients With Rilpivirine/ Tenofovir/ Emtricitabine (Single Tablet Regimen) in Russia. Value in Health, 2015, 18, A589.	0.3	0
128	Modeling of Using Rilpivirine/ Tenofovir/ Emtricitabine In Treatment of Na ⁺ ve Hiv-1 Infected Patiens. Value in Health, 2015, 18, A578.	0.3	0
129	Potential Long-Term Cost Savings In Treatment of Na ⁺ ve Hiv-Infected Patients With Rilpivirine/ Tenofovir/ Emtricitabine (Single Tablet Regimen) In The Russian Federation. Value in Health, 2015, 18, A581.	0.3	0
130	Budget Impact Analysis Of Formoterol Easyhaler In The Treatment Of Asthma In Children In The Russian Federation. Value in Health, 2015, 18, A497.	0.3	0
131	Cost-Effectiveness Analysis of Serelaxin in Treatment of Patients with Acute Decompensated Heart Failure. Value in Health, 2016, 19, A652.	0.3	0
132	Cost-Minimization Analysis of Lipegfilgrastim in Prophylaxis Of Febrile Neutropenia in Cancer Patients. Value in Health, 2016, 19, A723.	0.3	0
133	Cost Analysis of Intrathecal Baclofen Therapy For The Treatment of Spastic Cerebral Palsy In The Russian Federation. Value in Health, 2016, 19, A537.	0.3	0
134	Budget Impact Analysis of Acridinium Bromide In The Treatment of Chronic Obstructive Pulmonary Disease. Value in Health, 2016, 19, A550.	0.3	0
135	Budget Impact Analysis of Standard Care with Serelaxin in Treatment of Patients with Acute Decompensated Heart Failure. Value in Health, 2016, 19, A653.	0.3	0
136	Cost-Effectiveness Analysis of Lipegfilgrastim in Prophylaxis of Febrile Neutropenia in Cancer Patients. Value in Health, 2016, 19, A736.	0.3	0
137	Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir In Treatment Of Chronic Hepatitis C In The Russian Federation. Value in Health, 2016, 19, A415.	0.3	0
138	Cost-Effectiveness Analysis Of Daclatasvir With Asunaprevir Vs Paritaprevir/Ritonavir/Ombitasvir With Dasabuvir In Treatment Of Chronic Hepatitis C In The Russian Federation. Value in Health, 2016, 19, A415-A416.	0.3	0
139	Budget Impact Analysis of Sucroferric Oxyhydroxide in Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease. Value in Health, 2016, 19, A517.	0.3	0
140	Cost-Effectiveness Analysis of Sucroferric Oxyhydroxide in Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease. Value in Health, 2016, 19, A518.	0.3	0
141	Cost-Effectiveness Analysis Of Formoterol For Asthma Treatment In Russian Federation. Value in Health, 2016, 19, A115-A116.	0.3	0
142	Budget Impact Analysis Of Budesonide In The Treatment Of Asthma In Adult Population In Russian Federation. Value in Health, 2016, 19, A113.	0.3	0
143	Cost-Effectiveness Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A131.	0.3	0
144	Cost-Effectiveness Analysis Of 10% Intravenous Immunoglobulin Compared With Plasma Exchange In Treatment Of Children With Guillain-Barré Syndrome In Russia. Value in Health, 2017, 20, A753.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Budget Impact Analysis of Same And Mixed Budesonide And Formoterol Inhalers In The Treatment of Asthma In Russian Federation. Value in Health, 2017, 20, A641.	0.3	0
146	Cost-Effectiveness Analysis of Standard Therapy with Phosphocreatine VS Standard Therapy In Perioperative Management of Cardiac Surgery Patients With Extracorporeal Circulation, With Ischemic Heart Disease or With Chronic Heart Insufficiency. Value in Health, 2017, 20, A616-A617.	0.3	0
147	Comparison of Budesonide Inhalers For Treatment of Asthma In Adults And Adolescents In Russian Federation: Cost " Effectiveness Analysis. Value in Health, 2017, 20, A646.	0.3	0
148	Cost "Utility Analysis of Two Budesonide Inhalers For Treatment of Asthma In Children In Russian Federation. Value in Health, 2017, 20, A646-A647.	0.3	0
149	Cost-Minimization Analysis of 10% Intravenous Immunoglobulin In Treatment Of Primary Immunodeficiencies In Children In The Russian Federation. Value in Health, 2017, 20, A551.	0.3	0
150	Economic Evaluation of 10% Intravenous Immunoglobulin In Treatment of Primary Immunodeficiencies In Adults In The Russian Federation. Value in Health, 2017, 20, A551.	0.3	0
151	PRS48 - COST " EFFECTIVENESS ANALYSIS OF VILANTEROL/FLUTICASONE FUROATE FOR ASTHMA TREATMENT IN THE RUSSIAN FEDERATION. Value in Health, 2018, 21, S412.	0.3	0
152	PRS2 COST ANALYSIS FOR THE TREATMENT OF SEVERE UNCONTROLLED BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. Value in Health Regional Issues, 2019, 19, S77.	1.2	0
153	PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S672-S673.	0.3	0
154	PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S679.	0.3	0
155	PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S575.	0.3	0
156	PDB12 BUDGET IMPACT ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. Value in Health Regional Issues, 2019, 19, S30.	1.2	0
157	PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION. Value in Health Regional Issues, 2019, 19, S36.	1.2	0
158	PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S903.	0.3	0
159	PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S905.	0.3	0
160	PDB4 COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES. Value in Health Regional Issues, 2019, 19, S29.	1.2	0
161	PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION. Value in Health, 2019, 22, S848.	0.3	0
162	PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. Value in Health Regional Issues, 2019, 19, S30.	1.2	0

#	ARTICLE	IF	CITATIONS
181	Pharmacoeconomic analysis of modern Insulin analogues in the treatment of diabetes mellitus type 2. Pharmacoeconomics Theory and Practice, 2014, 2, 67-70.	0.1	0
182	Pharmacoeconomic study of botulinum toxin type A in treatment of post-stroke spasticity in the upper limb. Pharmacoeconomics Theory and Practice, 2014, 2, 38-46.	0.1	0
183	Pharmacoeconomic evaluation of axitinib introduction in metastatic renal cell carcinoma treatment scheme. Pharmacoeconomics Theory and Practice, 2014, 2, 77-81.	0.1	0
184	Pharmacoeconomic evaluation of Sitagliptin compared to sulfonylurea derivatives in patients with type 2 diabetes not controlled by Metformin monotherapy. Pharmacoeconomics Theory and Practice, 2014, 2, 51-54.	0.1	0
185	Financing of healthcare system at the regional level. Interrelation of qualitative and quantitative parameters with the scope of healthcare financing. Pharmacoeconomics Theory and Practice, 2014, 2, 75-80.	0.1	0
186	Pharmacoeconomic study of herceptin [®] (trastuzumab) for breast cancer patients. Pharmacoeconomics Theory and Practice, 2014, 2, 50-53.	0.1	0
187	Pharmacoeconomic study of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 61-65.	0.1	0
188	Pharmacoeconomic study of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 61-65.	0.1	0
189	Pharmacoeconomic analysis of evirola (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 44-51.	0.1	0
190	Pharmacoeconomic analysis of evirola (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 44-51.	0.1	0
191	Pharmacoeconomic analysis of evirola (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 44-51.	0.1	0
192	Pharmacoeconomic analysis of evirola (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 44-51.	0.1	0
193	A pharmacoeconomic analysis of ibrutinib in the treatment of mantle cell lymphoma. Pharmacoeconomics Theory and Practice, 2015, 3, 31-34.	0.1	0
194	Pharmacoeconomic analysis of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 61-65.	0.1	0
195	Pharmacoeconomic analysis of kadcyla (trastuzumab emtansine) in the treatment of patients with her2-positive breast cancer. Pharmacoeconomics Theory and Practice, 2015, 3, 28-31.	0.1	0
196	Validation of the pharmacoeconomic model of emtricitabin/ rilpivirine/ tenofovir (evirola) inclusion in highly active antiretroviral therapy of HIV/AIDS in the Russian Federation. Pharmacoeconomics Theory and Practice, 2015, 3, 86-87.	0.1	0
197	Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens. Onkourologiya, 2015, 11, 40.	0.3	0
198	Pharmacoeconomics study of canakinumab in patients with cryopyrin-associated periodic syndromes		

#	ARTICLE	IF	CITATIONS
199	Pharmacoeconomic study of buserelin-depo in the treatment of hormone-dependent prostate cancer. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 44-47.	0.1	0
200	Pharmacoeconomic analysis of implementation of clotting factor VIII and von Willenbrand factor medical products into the treatment regimens for von Willebrand disease. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 20-24.	0.1	0
201	Pharmacoeconomic study of canagliflozin (invocana) therapy as a part of combined therapy for patients with type 2 diabetes mellitus. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 55-61.	0.1	0
202	Pharmacoeconomic evaluation of targeted therapy in patients with systemic lupus erythematosus. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 98-102.	0.1	0
203	Pharmacoeconomic analysis of treatment of patients with severe and moderate ischemic stroke (NIHSS) Tj ETQq1 1,0.784314 rgBT /Ov	0.1	0
204	Pharmacoeconomic analysis of ryzodeg [®] , a combination of soluble ultra-long-acting human insulin analogue (insulin degludec) and ultra-short insulin analogue (insulin aspart), use in therapy of type 2 diabetes. <i>Pharmacoeconomics Theory and Practice</i> , 2015, 3, 61-66.	0.1	0
205	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 131-138.	0.1	0
206	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 131-138.	0.1	0
207	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 131-138.	0.1	0
208	Pharmacoeconomic analysis of medicinal drug fosinopril in patients with arterial hypertension. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 80-87.	0.1	0
209	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 131-138.	0.1	0
210	Pharmacoeconomic analysis of lapatinib treatment in metastatic breast cancer with HER2+ overexpression. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 62-69.	0.1	0
211	Pharmacoeconomic analysis of use of specialized health food line «MDMIL PKU» in children from birth compared with diet therapy, started in later periods. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 44-52.	0.1	0
212	Pharmacoeconomic analysis of metformin extended-release form using in diabetes mellitus type 2 treatment. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 96-101.	0.1	0
213	Pharmacoeconomic evaluation of dabrafenib in patients with unresectable or metastatic melanoma with BRAF V600 mutation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 110-115.	0.1	0
214	Pharmacoeconomic analysis of combination of medicines daclatasvir and asunaprevir in treatment of chronic hepatitis C in the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 131-138.	0.1	0
215	A pharmacoeconomic analysis of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 29-33.	0.1	0
216	Pharmacoeconomic analysis of trastuzumab application for subcutaneous administration compared to intravenous administration in the treatment of HER2-positive breast cancer in regions of the Russian Federation. <i>Pharmacoeconomics Theory and Practice</i> , 2016, 4, 70-74.	0.1	0

#	ARTICLE	IF	CITATIONS
235	PHARMACOECONOMIC EVALUATION OF BIOLOGICAL DRUGS IN THE CROHNâ€™S DISEASE TREATMENT IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 6-16.	0.1	0
236	BUDGET IMPACT ANALYSIS OF SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 23-28.	0.1	0
237	METHODOLOGICAL ISSUES OF COMPUTATIONS OF THE ENTRY AND DISTRIBUTION OF PATIENTS AND DETERMINING THE COURSE DOSE OF DRUGS IN PHARMACOECONOMIC MODELS. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 6-10.	0.1	0